Israel-based DiA Imaging inks deal with GE Healthcare on ultrasound devices

DiA Imaging inks deal with GE Healthcare on ultrasound device software development.

DiA Imaging Analysis, a medical imaging software company based in Israel, has inked a deal with GE Healthcare to develop automated imaging analysis technology. 

The deal is a multiyear, nonexclusive licensing and professional services arrangement, the company said. Financial terms weren’t disclosed.

Under the agreement, DiA Imaging will work with GE to use its technology for point-of-care environments. The company touts its analysis software as being able to give accurate, real-time imaging and analysis of ultrasound readings. Its technology uses pattern recognition and machine learning algorithms to give physicians and health-care providers a much-improved monitoring tool for the condition of a patient. 

FREE DAILY NEWSLETTER

Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

“Our advanced automated tools for point of care echo ultrasound analysis are first to market, and we are planning to soon launch additional automated imaging analysis tools as part of our vision to improve patient care,” Hila Goldman Aslan, DiA's chief executive officer and co-founder, said in a statement.

The company’s primary focus is currently on echocardiography. Its technology, which has been cleared by the FDA and has a CE mark, uses software that mimics the way the human eye identifies borders and motion, producing accurate and reliable data.

In the field of ultrasound, late last month Butterfly Network’s ultrasound-on-a-chip technology was cleared by the FDA for 13 applications, the broadest clearance to date for an ultrasound transducer. The pocket-sized transducer, which plugs into an iPhone, would expand the availability of diagnostic ultrasound imaging.

Philips is also working on a hand-held ultrasound, but its Lumify smart-device system uses three transducers like traditional systems. A year ago, the FDA cleared a cardiac transducer for use with Lumify, alongside two other transducers for OB/GYN and focused assessment with sonography for trauma examinations.

Suggested Articles

What the NASH field needs, says Genfit CEO Pascal Prigent, is something like the Hb1Ac test for diabetes.

Dubbed “Project Nightingale,” the efforts were announced amid concerns and federal inquiries into the data’s safekeeping and patient consent for use.

Exact Sciences received an FDA breakthrough designation for its liver cancer blood test as it finalized its $2.8 billion merger with Genomic Health.